Abstracts tagged "belimumab and clinical trials"

Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Mimi Kim¹, Kith Pradhan ¹, Peter Izmirly ², Kenneth Kalunian ³, Leslie Hanrahan ⁴ and Joan Merrill ⁵, ¹Albert Einstein College of Medicine, Bronx, NY, ²New York University School of Medicine, New York, ³University of California at San Diego, San Diego, ⁴Lupus Foundation of America, Washington DC, ⁵Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…
Abstract Number: 2189 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjögren’s Syndrome: Results of the Beliss Study
Salvatore De Vita¹, Raphaèle Seror², Luca Quartuccio³, Frederic Desmoulins⁴, Sara Salvin⁵, Gabriel Baron⁶, Martina Fabris⁷, Philippe Ravaud⁸, Miriam Isola⁹ and Xavier Mariette¹⁰, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, LE Kremlin-Bicetre, France, ³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁵Rheumatology Clinic, DSMB, University of Udine,, Udine, Italy, ⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ⁷Institute of Clinical Pathology, Udine, Italy, ⁸Epidemiology, Université Paris-Descartes, Paris, Paris, France, ⁹Institute of Statistics, DSMB, University of Udine, Udine, Italy, ¹⁰Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: to report the effects of anti-BAFF/BLyS antibody belimumab (BEL) on the different ogan manifestations of primary Sjögren’s syndrome (pSS), by evaluating the ESSDAI score…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].